Amarin Corp. PLC (AMRN) is a novel biotherapeutics company engaged in the development of treatment for cardiovascular diseases. The pipeline product candidate of the company is VASCEPA used as a diet adjunct to drop the level of triglyceride in hypertriglyceridemia patients.
The price of AMRN stock during the regular trading on January 24, 2022 with a sip of 2.61% was $2.99. At last check in the aftermarket, the stock was significantly up by 6.35%.
AMRN: Events and Happenings
On January 24, 2022, AMRN reported about the recent SEC filing by the filer reporting the company’s common stock owned shares in a public company. On January 10, 2022, AMRN reported its preliminary 2021 full-year revenue outcomes. The company expected a 2021 full-year and Q4 revenue to be approximately $580 million and $140 million respectively.
AMRN: CEO Comments
Speaking at the occasion, AMRN CEO Karim Mikhail said that the company is developing a fixed dose combination of VASCEPA and a statin. He further added that the company’s vision to reduce heart diseases is the sole driver to the fast delivery of results.
On January 04, 2022, AMRN reported that the company’s Executives presented at the Virtual 40th Annual J.P. Morgan Healthcare Conference held on January 11, 2022. On November 15, 2021 AMRN reported that the VASCEPA data was presented at the American Heart Association Virtual Scientific Sessions 2021 held on November 13-15, 2021.
On November 11, 2021, AMRN reported that the company’s Executives presented at the two investor conferences. They include Jefferies 2021 London Healthcare Conference held on November 16 and Virtual Piper Sandler 33rd Annual Healthcare Conference on November 22, 2021.
AMRN: Key Financials
On November 3, 2021, AMRN reported its financial results for the quarter ended September 30, 2021. Some of the key updates are as follows.
Revenue and Assets
Total revenue in Q3 2021 was $142 million versus $156 million in same period of 2020. Total current assets in Q3 2021 were $963 million.
Net Loss per Share
Basic and diluted net loss per share in Q3 2021 was $13.1 million or $0.03 versus $6.7 million or $0.02 in Q3 2020.
Conclusion
AMRN stock dipped 24% from the past six months period due to restrains put by the pandemic on the economic growth. The aftermarket stock increase is likely due to company’s recent SEC filing. The financial experts believe that, with this pace of strategic developments by the company, it will be able to attract the investors, despite its legal challenges .
